Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
CD98 identified as a key mediator of pro-fibrotic and acute inflammatory responses in the lung

CD98 identified as a key mediator of pro-fibrotic and acute inflammatory responses in the lung

How can we map the human genetic architecture of COVID-19 across all ancestry groups?

How can we map the human genetic architecture of COVID-19 across all ancestry groups?

New AI algorithm accurately and quickly diagnoses idiopathic pulmonary fibrosis

New AI algorithm accurately and quickly diagnoses idiopathic pulmonary fibrosis

Study offers insight into the basic cellular pathologies driving interstitial lung disease

Study offers insight into the basic cellular pathologies driving interstitial lung disease

Y chromosome loss in men can lead to deadly heart failure, research shows

Y chromosome loss in men can lead to deadly heart failure, research shows

Novel inhalable COVID-19 vaccine

Novel inhalable COVID-19 vaccine

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Zinc may reverse lung damage, improve survival for patients with idiopathic pulmonary fibrosis

Zinc may reverse lung damage, improve survival for patients with idiopathic pulmonary fibrosis

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation

Biomarkers to identify SARS-CoV-2 patients requiring invasive mechanical ventilation

Orally-active senolytics can boost a key beneficial protein in mice and humans

Orally-active senolytics can boost a key beneficial protein in mice and humans

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Study shows positive outcomes in COVID-19 patients who underwent lung transplants

Study shows positive outcomes in COVID-19 patients who underwent lung transplants

Scientists discover new insights about lymphangioleiomyomatosis

Scientists discover new insights about lymphangioleiomyomatosis

Composition of microbes in the lower airways is different for patients with idiopathic pulmonary fibrosis

Composition of microbes in the lower airways is different for patients with idiopathic pulmonary fibrosis

Role of leptin in immune modulation and pathophysiology of COVID-19

Role of leptin in immune modulation and pathophysiology of COVID-19

Correlation between idiopathic pulmonary fibrosis and COVID-19

Correlation between idiopathic pulmonary fibrosis and COVID-19

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.